Among the filamentous (mold) fungal infections, those caused by Aspergillus fumigatus and other Aspergillus spp. are the most common; these infections are associated with high morbidity and mortality, especially in the immunocompromised host (3, 7, 15, 33) . The triazoles itraconazole, voriconazole, and posaconazole have a broad spectrum of in vitro activity against molds and are important therapeutic agents for the systemic treatment and prevention of severe mold infections, including aspergillosis (33). Although acquired azole resistance in Aspergillus spp. has been documented since the late 1990s (8), it was uncommon. However, these reports have increased in the last few years, especially in Europe (4, 13, 24, 25, 31). The azoles act by blocking the pathway of ergosterol biosynthesis, specifically the enzymes 14-␣-sterol demethylases A and B. These cytochrome enzymes are encoded by cyp51 (A and B) genes in A. fumigatus and other Aspergillus spp. (19). More importantly, multiazole resistance or cross-resistance has been associated with point mutations in the cyp51A gene in A. fumigatus by substitution of the glycine at position 54 and methionine at position 220 by different amino acids (4, 9, 12), but substitution of L98H and 2 copies of 34 bp in the cyp51A promoter and other mutations also have been identified (13, 16, 20, 25, 31) . The TR/L98H point mutation has been responsible for an increased level of cyp51A expression (25, 29, 31) , and several mutations have been associated with patient failure on triazole treatment (13, 29, 31); however, other host and drug factors cannot be ignored (e.g., azole bioavailability).
Among the filamentous (mold) fungal infections, those caused by Aspergillus fumigatus and other Aspergillus spp. are the most common; these infections are associated with high morbidity and mortality, especially in the immunocompromised host (3, 7, 15, 33) . The triazoles itraconazole, voriconazole, and posaconazole have a broad spectrum of in vitro activity against molds and are important therapeutic agents for the systemic treatment and prevention of severe mold infections, including aspergillosis (33) . Although acquired azole resistance in Aspergillus spp. has been documented since the late 1990s (8) , it was uncommon. However, these reports have increased in the last few years, especially in Europe (4, 13, 24, 25, 31) . The azoles act by blocking the pathway of ergosterol biosynthesis, specifically the enzymes 14-␣-sterol demethylases A and B. These cytochrome enzymes are encoded by cyp51 (A and B) genes in A. fumigatus and other Aspergillus spp. (19) . More importantly, multiazole resistance or cross-resistance has been associated with point mutations in the cyp51A gene in A. fumigatus by substitution of the glycine at position 54 and methionine at position 220 by different amino acids (4, 9, 12) , but substitution of L98H and 2 copies of 34 bp in the cyp51A promoter and other mutations also have been identified (13, 16, 20, 25, 31) . The TR/L98H point mutation has been responsible for an increased level of cyp51A expression (25, 29, 31) , and several mutations have been associated with patient failure on triazole treatment (13, 29, 31) ; however, other host and drug factors cannot be ignored (e.g., azole bioavailability).
The Clinical and Laboratory Standards Institute (CLSI) has developed a reference broth microdilution method for antifungal susceptibility testing of molds (CLSI M38-A2 document) (5) . The availability of reference methodologies has enabled the recognition of the complexity of cross-resistance among triazoles (9, 18, 20, 22, 24, 25) and the proposal for epidemiologic cutoff values (ECVs) for A. fumigatus and itraconazole, posaconazole, and voriconazole by both CLSI (22) and the European Committee of Antibiotic Susceptibility Testing (AFST-EUCAST) (24) methodologies. Clinical breakpoints are not available for mold testing by the CLSI methodology versus any antifungal agent. However, breakpoints based on MIC distributions, pharmacokinetic and pharmacodynamic (PK/PD) parameters, animal data, and clinical experience have been proposed for the EUCAST reference method for A. fumigatus and the three triazoles (30) . In the absence of clinical breakpoints, ECVs could help to characterize the susceptibility of Aspergillus isolates to itraconazole, posaconazole, and voriconazole and to monitor the emergence of strains with mutations in the cyp51A gene and/or reduced antifungal triazole activity. Although the incidence of other species such as A. flavus, A. niger, and A. terreus, among others, has increased as the cause of severe opportunistic infections (7, 17) , neither ECVs nor breakpoints have been proposed for these other Aspergillus spp. For the first time, we are proposing ECVs for itraconazole, posaconazole, and voriconazole against five species of Aspergillus (A. flavus, A. nidulans, A. niger, A. terreus, and A. versicolor) and have expanded prior ECV data for A. fumigatus by using a substantially higher number of isolates. The dual purpose of the study was (i) to define the wild-type (WT) distributions of each species/agent combination by using aggregated MIC data gathered in five laboratories in Europe and the United States (45 to 2,815 MICs per species/triazole combination) and (ii) to propose ECVs for each species/agent combination.
MATERIALS AND METHODS
Isolates. Each isolate was recovered from unique clinical specimens at five medical centers: the University of Texas Health Science Center, San Antonio, TX; the HPA Centre for Infections, Kingsdown, Bristol, United Kingdom; the Hospital General Universitario Gregorio Marañón, Madrid, Spain; the University of Iowa College of Medicine, Iowa City, IA; and VCU Medical Center, Richmond, VA. Isolates were identified and stored at each medical center using standard methodology. The total number of isolates varied according to the species and antifungal agent combination being evaluated, with the lower number of isolates being tested with posaconazole and the higher number being tested with voriconazole (1,684 to 2,815 isolates of A. fumigatus, 323 to 592 of A. flavus, 131 to 143 of A. nidulans, 366 to 520 of A. niger, 330 to 462 of A. terreus, and 45 to 84 of A. versicolor). The reason was that we have aggregated the maximum available MIC data from the five laboratories for each combination and that never provided an equal number of isolates. For example, the total number of isolates for which voriconazole, itraconazole, and posaconazole MICs were available was 4,614, 4,181, and 2,879, respectively; the MIC contribution from each of the five laboratories also varied among 33.5, 32, 15.3, 10, and 9.2%, respectively, for voriconazole; the MIC contribution from each laboratory for the other two agents was similar to that for voriconazole.
Among the total set of isolates, 86 had itraconazole MICs of Ն4 g/ml; these isolates were subtracted from the whole set for ECV calculations to ensure that the ECV separated the drug-susceptible WT fungal organisms from those that showed a deviation in the susceptibility profile. Also, there were well-characterized itraconazole-susceptible and -resistant A. fumigatus isolates: two resistant (MIC, Ն4 g/ml) and four susceptible (MICs, Յ1 g/ml) with clinical, animal model, and resistance mechanism data (8) . In addition, one voriconazole-resistant laboratory mutant (MIC, Ն4 g/ml) and two isolates with a voriconazole MIC increase (more than 2 doubling dilutions) during voriconazole therapy were included (10, 11) . Three quality control (QC) isolates (Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, and Paecilomyces variotii ATCC MYA-3630) (5) were used by the participant laboratories; Table 1 depicts the QC data for these isolates.
Antifungal susceptibility testing. In order to include MIC results in the total set (Table 2) , each available MIC of itraconazole, posaconazole, and voriconazole was obtained in each center by following the CLSI M38-A2 broth microdilution method (standard RPMI 1640 broth [0.2% dextrose], final inoculum concentrations that ranged from 0.4 ϫ 10 4 to 5 ϫ 10 4 CFU/ml, and 48 h of incubation); MICs were the lowest drug concentrations that produced complete growth inhibition (100%) (5) . One of the three QC strains was utilized during the years of testing.
Definitions. WT is the population of organisms/MICs in a species/drug combination with no detectable acquired resistance mechanisms (6, 14, 26, 27) . The high WT MIC has been defined as either the WT cutoff value (COwt) or the ECV; the latter term has been previously used in similar fungal reports (22, 23, 24) , and it is the term used throughout the present study.
Data analysis. The MIC distribution of each species/combination from each laboratory was first screened for signs of skewed results, and modal MICs were determined for data from each laboratory. In addition and as mentioned above, isolates for which itraconazole MICs were Ն4 g/ml were subtracted from each distribution, regardless of the correspondent posaconazole or voriconazole MIC. In this way, we ensured that the ECV separated the drug-susceptible WT organisms from those having acquired or mutational azole resistance (e.g., Aspergillus isolates that showed a deviation in the susceptibility profile to the triazole being evaluated compared to that shown by the WT population). All percentages were obtained using these lower numbers of isolates, except for those results concerning non-WT isolates/MICs. The WT distributions of the aggregated data from the five laboratories for each triazole/species combination were obtained, and the ECV was defined by taking into consideration the modal MIC (most frequent) for each distribution of aggregated MICs for each species and drug, the inherent susceptibility test variability (Ϯ1 log 2 dilution), and the high WT MIC that accommodated Ն95% of each MIC distribution (22, 23) . This type of analysis is considered the "eyeball" technique, in contrast to the statistical method, where the modeled population is based on fitting a normal distribution at the lower end of the MIC range, working out the mean and standard deviation of that normal distribution, and using those numbers to calculate what MIC captures 95% or higher percentages (e.g., 99%) of that distribution; this analysis was also performed (14, 26, 27) .
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RESULTS AND DISCUSSION
The utility of susceptibility testing is achieved when the test result can define the susceptibility or resistance of the organism being tested against a specific agent. The drug concentration that classifies the organisms as treatable or nontreatable or the predictor of clinical outcome is now defined as the clinical breakpoint (6, 27) . Clinical breakpoints are established based on clinical trial data, global susceptibility surveillance, resistance mechanisms, and PK/PD parameters from model systems. Clinical breakpoints are not available for mold testing owing to the low volume of mold infections and the scarcity of isolates with high MICs during clinical trials. Enough in vitro data have been accumulated throughout the years, however, to enable the definition of ECVs for A. fumigatus and the triazoles (22, 24) . In the present study, ECVs for five other species of Aspergillus were defined and the ECV for A. fumigatus was also reevaluated (22, 24) . These ECVs may aid in the evaluation of clinical isolates by identifying those strains with reduced triazole susceptibility due to cyp51A mutations and may serve as an early warning of emerging subtle changes in the susceptibility patterns of these organisms.
Variability is expected when MICs from different laboratories are compared despite standardization efforts, including the interlaboratory variation that has been observed under controlled conditions with single strains in QC or in collaborative studies designed to identify optimal testing conditions for Aspergillus testing (10) . Table 1 depicts the MIC data for the three QC isolates obtained in each participant laboratory when clinical isolates were tested. Although most values were within CLSI 3 to 4 dilution MIC limits (98 to 100%) for these QC strains (5), the modes were variable (mostly Ϯ1 dilution). This modal MIC variability among the five laboratories for the QC strains reflected the differences observed among the modal MICs for clinical isolates for some species/drug combinations. Because of that, various posaconazole and itraconazole MIC distributions for A. fumigatus and A. flavus did not appear to conform as well to a "normal distribution" (Table 2) . These "abnormal" distributions (shoulders adjacent to the designed modal MIC, bimodal distribution ["saddle" between two modes], and similar bar sizes) have also been previously observed from single laboratories for the triazoles and A. fumigatus (22, 30) . Another possible source of variability could have been the use of different lots of antifungal powders since testing was performed over the course of many years in order to accumulate these large numbers of MICs. These sources of variation have never been formally explored, but they could be due just to individual interpretations of MIC endpoints as our results for the QC isolates suggest.
The aggregated WT MIC distributions for each species and each triazole evaluated are depicted in Table 2 ; the 86 isolates for which itraconazole MICs were Ն4 g/ml (values within parentheses) are also displayed in this table. fumigatus and posaconazole, voriconazole, and itraconazole, the modal MICs were 0.06, 0.25, and 0.5 g/ml, respectively. The itraconazole distribution for this species showed a prominent shoulder at the MICs of 0.25 g/ml, more likely due to different modal MICs from the laboratories (0.5 g/ml at three laboratories and 0.25 g/ml at two laboratories). The posaconazole distribution had similar-size bars at MICs of 0.03 and 0.06 g/ml, which means that the mode lies between those two concentrations; similar-size bars were also observed with voriconazole. This type of MIC distribution abnormality has been previously reported for A. fumigatus with itraconazole (22, 30) and posaconazole (30) . Most of our modal values were either the same as or 1 dilution higher than those in previous ECV reports (22, 24) , which indicated again that on average some laboratories were reading either lower or higher MICs (Ϯ1 dilution). Each modal MIC plus or minus one 2-fold dilution comprised approximately 73% of the isolates for posaconazole, 75.6% of the isolates for itraconazole, and 86.8% isolates for voriconazole.
As in prior studies (22, 24, 30) , the ECV was 1 g/ml (encompassing 97.7 and 98.8% of isolates, respectively) for A. fumigatus and both voriconazole and itraconazole ( Table 3 ). The frequency of voriconazole MICs of Ն2 g/ml (non-WT isolates) for A. fumigatus was 3.1% (88 isolates) (Tables 2 and  4) , and it was similar to or higher than (Յ4.8%, Յ17 isolates) that previously described (22, 24) . Our set of isolates was much larger (2,815 isolates with voriconazole MICs versus less than 400 isolates in both prior studies) and came from various geographical areas. However, the rate of itraconazole and voriconazole MICs of Ն2 g/ml was higher (ϳ30%) in the Nijmegen collection (30) despite that group's lower sample size (325 isolates); 2.6% of non-wild-type itraconazole MICs (68 of 2,591 isolates) were observed in the present study. These regional differences underscore the utility of susceptibility testing and WT cutoffs as a practical means to detect azole resistance.
Based on the Ն95% inclusion eyeball methodology used in our study to define ECVs (22, 23), our ECV for A. fumigatus and posaconazole was 0.5 g/ml (99.2%) or 1 dilution higher than that in two of the three previous reports (22, 24) ; the MIC of 0.25 g/ml included only 93.4% of the isolates. However, the statistical calculation defined the ECV for A. fumigatus and posaconazole as either 0.25 g/ml (95% MIC inclusion) or 0.5 g/ml (99% MIC inclusion); this method uses a modeled population and the upper parts of any bimodal distributions are excluded. Both eyeball and calculated ECVs are listed in Table  3 . In the third study (30) , the ECV should also have been 0.5 g/ml, because 18.5% (60 of 325) of posaconazole MICs were 0.5 g/ml compared to 6.1% (103 of 1,684) in our study (Table  2) . However, those authors defined their endpoints as "breakpoints" and posaconazole MICs of 0.5 g/ml as "intermediate" instead of "susceptible." Their reason was the limited ability to increase posaconazole exposure with the oral solution. Therefore, they were not bound by the requirements of the Ն95% inclusion of values. The other factor considered in that study was that results in an animal model of A. fumigatus (cyp51A mutations) and posaconazole suggested that when the posaconazole MIC for the infecting isolate was 0.5 g/ml, the standard dosing regimen needed to be increased to avoid failure (18) . Nevertheless, data from our study and the third prior study (30) indicate that high posaconazole MICs are a frequent occurrence. Based on preliminary animal data and drug exposure issues, an isolate for which the MIC is above 0.25 g/ml a Non-WT isolates are isolates for which either itraconazole, posaconazole, or voriconazole MICs were higher than the defined ECV among the total of isolates tested including those isolates for which high itraconazole MICs (Ն4 g/ml) were determined. may suggest a reduced susceptibility to this agent. Therefore, further research is needed to clarify these conflicting results and to determine the utility of these results in patient management.
ECVs for A. flavus and A. terreus (323 to 592 isolates, species/agent combination dependent) were mostly the same (0.5 to 1 g/ml) as those for A. fumigatus; the exception was the lower ECV for A. flavus and posaconazole (0.25 g/ml) ( Table  3 ). The modal MICs were either the same or within Ϯ1 dilution for both species with voriconazole and itraconazole (0.25 to 0.5 g/ml). However, the distribution of itraconazole MICs for A. flavus showed a "saddle" between the mode and the MIC of 0.12 g/ml, because the bulk of MICs were either 0.12 or 0.5 g/ml; similar mode variation was seen for the QC isolates (Tables 1 and 2 ). The posaconazole modal MIC was 2 dilutions higher for A. terreus than for A. flavus (0.25 versus 0.06 g/ml). The modal MICs plus or minus one 2-fold dilution for A. flavus comprised approximately 64.6% of the isolates for itraconazole, 77.6.2% of the isoaltes for posaconazole, and 95.4% of the isolates for voriconazole; for A. terreus the value encompassed approximately 67.5% of the isolates for itraconazole, 78.2% of the isolates for posaconazole, and 91.3% of the isolates for voriconazole.
There were four itraconazole MICs above the ECV or non-WT isolates (0.7%, Ͼ1 g/ml) for A. flavus, while there were 12 voriconazole MICs (2%) and 18 posaconazole MICs (5.6%) above the ECVs of these two other agents (Ͼ1 and Ͼ0.25 g/ml, respectively) ( Table 4) . There were only a few non-WT isolates (Ͼ1 and Ͼ0.5 g/ml, respectively) in the itraconazole and posaconazole distributions for A. terreus (1 isolate, 0.3%, and 0 isolates, respectively), but in contrast there were 14 MICs (3%) above the voriconazole ECVs (Ͼ1 g/ml). The highest voriconazole MIC for A. terreus has usually been 1 g/ml by the CLSI M38-A method (2, 11) but 4 g/ml by the EUCAST method (17) . Again, our unusual number of high voriconazole MICs for A. terreus may be due to the large number of isolates (n ϭ 462) from various geographical areas; however, the lack of previous ECV reports for non-A. fumigatus isolates has precluded comparisons. The incidence of isolates with apparent reduced susceptibility to voriconazole is worrisome since A. terreus has increased in frequency and both in vitro and in vivo resistance to amphotericin B, another important therapeutic agent for aspergillosis, are quite common; voriconazole is the licensed agent for primary therapy of systemic aspergillosis (33) .
The presence of cyp51 genes in A. flavus has been reported since 2001 (19 [16] ). As for A. fumigatus, cyp51Ap gene modifications also appeared to be responsible for in vitro azole resistance in this species. Therefore, extensive use of voriconazole prophylaxis in immunocompromised patients may lead to the selection of voriconazole-resistant A. flavus isolates (16) . To our knowledge, data regarding triazole molecular resistance mechanisms are not available for A. terreus, but the presence of the two cyp51 genes also was reported for this species as early as those for the other species (19) . Whether the reduced voriconazole activity for A. terreus is due to cyp51 amino acid changes is yet to be determined.
Our ECVs for A. niger (a Nigri group member) versus posaconazole, itraconazole, and voriconazole were 1 dilution higher (0.5 and 2 g/ml) than for the other three more common species discussed above (Table 3 ). The modal MICs plus or minus one 2-fold dilution for A. niger comprised about 58.8% of the isolates for posaconazole, 83.9% of the isolates for voriconazole, and 84.5% of the isolates for itraconazole. There were 41 (8.8%) and 19 (5.2%) isolates for which the itraconazole and posaconazole MICs were above the susceptibility cutoff for A. niger (Ͼ2 and Ͼ0.5 g/ml, respectively) versus 68 isolates (2.6%) for A. fumigatus (Tables 2, 3 , and 4); these high MICs were reported from four of the five laboratories. This is a concern since A. niger is frequently involved in pulmonary aspergillosis and has been recently reported as the most frequent cause of otomycosis (7, 15) . By phylogenetic analyses of 34 isolates of the Nigri group, it was demonstrated that A. tubingensis and A. foetidus had unusually reduced susceptibility to the triazoles (most itraconazole MICs, Ն4 g/ml; voriconazole MICs, 2 g/ml; and posaconazole MICs, 0.12 to 0.5 g/ml) in contrast to A. niger (most itraconazole and voriconazole MICs, Յ1 g/ml, and posaconazole MICs, Ͻ0.12 g/ml) (1). Those two species morphologically resembled A. niger and required molecular methods for their proper identification. Acquired triazole resistance also has been documented in Europe for the A. niger complex (30) . Therefore, reduced azole susceptibility is to be expected in the Nigri group. Resistance mechanisms for the Nigri group have not been elucidated to our knowledge, but azole resistance has been associated with amplification of cypA in an engineered laboratory strain of A. niger (28) . Further research is needed to clarify these important issues.
Although the number of isolates for which MICs were available was much lower for A. nidulans (131 to 143 isolates) and A. versicolor (45 to 84 isolates) due to these species being less frequently associated with disease, the available MIC distributions warrant the proposal of tentative ECVs. Itraconazole, posaconazole, and voriconazole ECVs for A. nidulans and itraconazole and voriconazole ECVs for A. versicolor (1 to 2 g/ ml) were similar to those for A. niger. However, the eyeball cutoff for A. versicolor and posaconazole was 4 g/ml, but the statistically defined ECV was 1 g/ml. Although posaconazole MICs of Ն4 g/ml for six A. versicolor isolates were repeatedly determined and simultaneously tested with other isolates with low MICs and their identification was confirmed, no data are available regarding molecular mechanisms of resistance for these isolates. Because of that and due to the low number of A. versicolor isolates with available posaconazole MICs (45 isolates), we are proposing as a tentative ECV the calculated cutoff of 1 g/ml. It is noteworthy that posaconazole MICs of Ն4 g/ml have been recently determined for other isolates of this species.
The available in the literature regarding the susceptibility patterns of these two species to warrant comparisons (2, 11), but four to six of our triazole MICs were Ն4 g/ml for A. versicolor and one to two MICs were Ն4 g/ml for A. nidulans ( Table 2 ). The incidences of triazole MICs above the ECVs were similar for these two species (1.4 to 6.3% for A. nidulans and 5.6 to 13.3% for A. versicolor), but these percentages are based on a smaller number of isolates, especially for A. versicolor (Tables 2 and 4) .
Nevertheless, it appears that reduced susceptibility to the three triazoles, also reported for another uncommon species (A. ustus) (32), should be expected. These results underscore the need to perform antifungal susceptibility testing for these pathogens. Amplification or overexpression of the cyp51 gene in an A. nidulans laboratory mutant has been correlated with triazole resistance (21) , but data are not available from clinical isolates of this species or concerning cyp51 point mutations in A. versicolor.
The link between single and/or multiple triazole resistance with either point mutations and/or treatment failure has been demonstrated for A. fumigatus and A. flavus (12, 13, 16, 18, 19, 20, 24, 25, 29, 31) . In our study, we analyzed triazole crossresistance using data from the 86 isolates for which itraconazole MICs were Ն4 g/ml. We observed similar cross-resistances between itraconazole and posaconazole (35.1% of isolates within the ECV) and between itraconazole and voriconazole (32.4% of isolates within the ECV) for A. fumigatus (Table 5) . These results differed from a previous report where cross-resistance was evident between itraconazole and posaconazole (46.5% of isolates within the ECV) but not between itraconazole and voriconazole (93% of isolates within the ECV) (22) . Similar to our results, cross-resistance was observed between itraconazole (geometric mean [GM] MIC, 16 g/ml) and voriconazole (GM MIC, 3.7 g/ml) when isolates had substitutions of leucine for histidine as well as two copies of a 34-bp sequence in tandem in the gene. Also, crossresistance between itraconazole and posaconazole has been reported with other single mutations (posaconazole GM MICs, 0.65 to 1.6 g/ml) (24). Our results for A. niger show a low degree of cross-resistance with voriconazole (95% of isolates within the ECV) but a higher degree of cross-resistance with posaconazole (78% of isolates within the ECV). The number of isolates with high itraconazole MICs was much lower (none for A. terreus) for A. flavus, A. nidulans, and A. versicolor, but a similar degree of cross-resistance was evident among them ( Table 5 ). The lack of similar previous results has precluded comparisons for the non-A. fumigatus species. Although we do not have information regarding the molecular resistance mechanisms for the 86 isolates, our cross-resistance results were probably due to various point mutations (underlying resistance mechanism dependence), as previously demonstrated (16, 24) . Based on our and prior results (22, 24, 30) , a high triazole MIC for an Aspergillus isolate suggests a reduced susceptibility to one or both of the other two agents. The use of a nonazole agent has been recommended in the initial therapy for invasive aspergillosis when the infecting isolate is azole resistant (30) .
In summary, our data confirmed prior susceptibility cutoffs (1 g/ml) for the combinations of A. fumigatus versus itraconazole and voriconazole but suggested a new and tentative ECV for Aspergillus versus posaconazole. More importantly, ECVs for five other Aspergillus spp. have been proposed (0.25 to 2 g/ml, species/drug combination dependent). The similarity of ECVs for A. fumigatus and the three triazoles suggests that both CLSI and EUCAST methods essentially provide the same results. Our results also corroborated earlier European reports regarding the increasing incidence of triazole resistance in A. fumigatus and extended this evidence to other species, especially in A. niger and A. versicolor. Therefore, the availability of reference methodologies and ECVs for Aspergillus spp. offers a practical tool for the continued and necessary monitoring of the emergence and development of triazole resistance in Aspergillus spp. These ECVs should be considered for inclusion in future revised versions of the CLSI M38-A2 document. 
